N
Google TrendLAMINE YAMAL (2000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal2000+abdulrahman alfozan500+pope francis500+olise500+delaware vs middle tennessee prediction500+bayern de múnich200+gme1000+flashscore200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Induction chemo-immunothe" (30 stories)

Top Headline Story

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
Lead StoryNaturetech
Dec 23, 2025

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XTVdVbGl6cFVVbWNvaFIwbnJWd2NYemVkSUV3SGI0NFcweXplS3paSDFwV3YwUXhOWW5KTG5BaFZBN1pMc3VQaWt1TVN5OFZFQkZnZ0xnWmZyWXVjVFlr?oc=5" target="_blank">Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+23m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+33m ago

abdulrahman alfozan

OpenAI engineer arrested in bugging of executive conference room

Filter stories
500+33m ago

pope francis

The Myth of St. Francis

Filter stories
500+33m ago

olise

Bayern’s Michael Olise sent off for 2 yellow cards within seconds in Champions League

Filter stories

Search Results for "Induction chemo-immunothe"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy
Targeted Oncologygeneral

Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNSm5QMVhXZUw1emNzc3k1MVR4MDZnUUZ1RXBHeS1XdWdzb0J2RTVHSkY1U2IwWGZrbmlzRjROejctb2VQcFc5RjRDV2YwRm9oTkpaU3d2dm45WUhYNnBDS3VKdlFRTk9wV3RQdGo3OG9jRGoxbVF0em1HOW16TXJFNjBHTjZSUDBranFjRVd6VThfV3ozbnc?oc=5" target="_blank">Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Case Report: Early introduction of anti-GD2 immunotherapy during induction chemotherapy in high-risk neuroblastoma: two pediatric cases
Frontiersworld

Case Report: Early introduction of anti-GD2 immunotherapy during induction chemotherapy in high-risk neuroblastoma: two pediatric cases

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOSDhhXzlrYlp3WTI1VWRGZ0IxcHN2YWJQV2pWMkl2R3dHWHBBbC1nM05NaFVYZUpFb1RUR2VVeGc3a3MtdFZFeVoxT0FLaG5aNnlOVXFJVzRodWJ2eDJVcnNTUkR1THo2MHlqUG82ZEhQNmJPQ2pPT1pXZ0M5NFF4cjFBWUd2a21jajlGVEt3?oc=5" target="_blank">Case Report: Early introduction of anti-GD2 immunotherapy during induction chemotherapy in high-risk neuroblastoma: two pediatric cases</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer
Natureworld

Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5YekxWb3BfYzdGYTNOZ3l3ZWFNQ1VKRTBkcldPMFVPNV9iWXBGR2dWOVZIdVFHd2xWcGJyck9xOGtnOWQ4bllVQVBtQW5qaTFDYjlaUDdLYTZSblYzMGlR?oc=5" target="_blank">Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Low-Dose Immunotherapy: India’s Challenge to Conventional PD-1 Dosing
Oncodailyworld

Low-Dose Immunotherapy: India’s Challenge to Conventional PD-1 Dosing

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1TZWhGNm1uVnVYSUNIN2NwbTlvVy1vdGpQdVA4UW5ST2F2WnkxVWwzeklRekRwTU1EcHRKOHNyT3VjSnhDa0Q4UFMwTkFUTDNNb0I3NUlUWkk0aVo2YVRfVFFaazRuNk0?oc=5" target="_blank">Low-Dose Immunotherapy: India’s Challenge to Conventional PD-1 Dosing</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Case Report: a three-stage treatment strategy combining immunotherapy with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
Frontiersworld

Case Report: a three-stage treatment strategy combining immunotherapy with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNMXkxaXcyWVlEVXhPSlJaNmRydFJpWDRqaTc2NGVLeWMyc1FLWG5VYkdVNkotMW9kblBlalVWSnJjOW9qV2pvZmlVaWp1dG1sT0tnRTZQR2ZZeDlSTEttRC1QeFZKVWoxdnp4Qk0tbmlmN1dVZWFLMFlzRzBtNEtvOUtsRUh3MDhza25RS2I5bXEzUQ?oc=5" target="_blank">Case Report: a three-stage treatment strategy combining immunotherapy with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Phase 2 CHIMERA Trial Tests Neoadjuvant Pembrolizumab in Mesothelioma
Targeted Oncologygeneral

Phase 2 CHIMERA Trial Tests Neoadjuvant Pembrolizumab in Mesothelioma

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPNzNDalB3MERCT0NJQlZTZG1XZzU2TTRiLWM4WFQ2b3pRRlFXY3VzME1VREdacmpqX0FvMy1vdHVyY28zM1ZuXy15alBKWU5VaE9tS1BCNldnNE40ck1CQXVpU1M3aV9WcXBpZDNOcHh0WHVpWm5Vd19JMl9aT3M0T09UbEFILWttNW1vSk9kLUdISFBKVnpqTkFWSlQ5RXFEcDVwRg?oc=5" target="_blank">Phase 2 CHIMERA Trial Tests Neoadjuvant Pembrolizumab in Mesothelioma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Evaluating Whether Induction Chemoimmunotherapy Before CRT Fits Into the Treatment Landscape of LA-NSCLC
ASCO Daily Newsworld

Evaluating Whether Induction Chemoimmunotherapy Before CRT Fits Into the Treatment Landscape of LA-NSCLC

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOYjFmWk9vTFhQcWZVcnoxNnBYMWNjWWFOLVcwRGJ5aXozNkVJblRIYUdhU1BJdnhIN3RyVXM5Yk5mZ0VaNnRGRFBab09rTVZfU2hvQ1dmdnNkVU9UUngtYm1hcjZkUTB3amlPMzlBSk83X2NWeXlwOVQwNF9sYVBsSkNOdm1OV1RTSWZYc1dxUlJyT0lhcmFYU0t0S3lyY3FzWm5lcTRZYmNGZDlQUldHRWJn?oc=5" target="_blank">Evaluating Whether Induction Chemoimmunotherapy Before CRT Fits Into the Treatment Landscape of LA-NSCLC</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Durvalumab Plus Thoracic Radiotherapy Fails to Improve Survival in Extensive-Stage Small Cell Lung Cancer
Oncology News Centraltech

Durvalumab Plus Thoracic Radiotherapy Fails to Improve Survival in Extensive-Stage Small Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPYU4yWDFTU1dFZjdwX1JkdlNUVEFRWnFMTnNsN2x1WUE2eGxFUENCMlJTSmQtcmhwUFVCOFVHbjZ2dWxmVDJWSWpuRW9DM2lKQTZ2UWk0Y0FnZ1p5ZU1VOG1tOXVZdHNTWjMtc25lZ3dLWi0xZ0pFQ1JXYXFMUUNrSTJWMTBobUlsWkJNMXZLMlNkUURNdVJrQUhTbTFDaWduMXJoY05ybjJiSzY4SFZzcnhn?oc=5" target="_blank">Durvalumab Plus Thoracic Radiotherapy Fails to Improve Survival in Extensive-Stage Small Cell Lung Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial
Natureworld

Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE55dmFWdzJ1eFNPdW1ZV0MzNk5RQkZrVEpoTVFqUlp0b3NyZURKY0NFZy04RVNaTkhMajNueWs3RHZVWURjR3FhSXFlcTNnOGF1R2w2S2lSN2VfREZFa1I0?oc=5" target="_blank">Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer | Journal of Clinical Oncology
ASCO Publicationsworld

Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer | Journal of Clinical Oncology

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9vTDlDWmN5T181SmxFeUtnNUtIZUIzTVNHcGRqTmwzSWxjTk1xbzdES0E4RGtfRU8wTVZsdzdNaElTSTlEN2xtT1hzUFJXWFVLNGktdDVKRXU?oc=5" target="_blank">Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer | Journal of Clinical Oncology</a>  <font color="#6f6f6f">ASCO Publications</font>

Read Full StoryMore like this
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer
Natureworld

Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE16bUY4QkMwSG0xajkxQ25CTWkxQW5PTThWdkdpbl9Vd19WWldsSDJuNW9ZQ0hZVUpESW5mNWFLZ1QxVGN0MWxqWXI5eGNvRXFucmRZOXZLbUl3RklzcFpr?oc=5" target="_blank">Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare
Frontiersworld

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNTUU0bzVSRnppdmJSVDNtbXFjWFpDSU9jUHFHRzdhYXBwNVFfUURCMTd3NE9ScVB2R3QzREJncTZpSndFSG43T0Njb3k2X2hnUXZIOU1TQnlITnVHeHJSR3owck44bEhIdllPS0ZRRnJhMlMzTnEzZm45Um4weGZIUzhvRW40SzFwbTMtdjBR?oc=5" target="_blank">Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study | British Journal of Cancer
Naturetech

Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study | British Journal of Cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5iZG1TTEFXQjZLT1pjZy1KZURIMElvWWFzb1pZQ21kc21aSDhFdjlHbEExZmhTVEJCS3BQN0Q5SWZzRzhVN3NIOW41N2tLZ0M2OU5jbUR5Tmwzb3hKLU5j?oc=5" target="_blank">Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study | British Journal of Cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Redefining the concept of resectability in the landscape of perioperative treatments for lung cancer
Frontiersworld

Redefining the concept of resectability in the landscape of perioperative treatments for lung cancer

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNMHFtZnlzSkVGME5hS0NvbFRlM2hhR29wMUNzOXltY0NJVksySE82NzlRcDNfSGtHcU9obzFQZDhfTFl4RXNHZXJ4WXJCOE0yaXdMVktQLU5wNkNGZTFndkNlOHJSSFVpYkhUbUNBalJGT0tzclNFSzEzM2FPcWtyb2lvT0lKeXdqWjFfSGRn?oc=5" target="_blank">Redefining the concept of resectability in the landscape of perioperative treatments for lung cancer</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy
Natureworld

Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBaSTBRMEtvUVhzTUZhbXBQMWlsVDNYeE02YllkT0RqYWpXMHJQc1BmWTVfNGQxYWdaem5hdmc0MzNuNEVMWjFzOUtzTTJGM1BFNlgzZ1JJLUZmTlh1dWRJ?oc=5" target="_blank">Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis | British Journal of Cancer
Natureworld

Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis | British Journal of Cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXMFdpNV92MDJaSFB5Y0JtZkNzX1JUQ2Z6WFpySHk4ZDMzWjJGWXJfVTdWRnRkUUtRdXZ2QjVMTHlwOEhSZ00xNDl4Y2tpcUQ2clppM1o3SmhENUFwU2Ew?oc=5" target="_blank">Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis | British Journal of Cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial
Natureworld

Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xcE5kRFh5ekhZemMxQ0E2UG8yOU85dUJHbDVGeGNEeDdRYm5wemRvZ0ViWWZJU0FDZndMVHMtaDVsOTFBa3dGeURKV2J2cFJxRlVuRGdEbEYzQ0dCV0dV?oc=5" target="_blank">Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial
Natureworld

Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBSTjlsejQwSXpLb1huanlDdW5OQWZiU1FKUzR6U2ZVS2tfem0wRHc3c1h4WTR6Zjd5SW4ydzB0cU5tcWxhQmpkZmJOVThfUW4xNXNwZGpMUUtyMVlYTTIw?oc=5" target="_blank">Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
Natureworld

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBlbFVxeWZISGNiQWxPVXRCQ0RZS3JaT2E2YktFMFRJN3FsVVMzcWxUVXBaSm5BYUxNSzRnS0VON0ViSHdmOG5DNXlZeHNKaG5OWFJuclhjdEZaU0pQa3Aw?oc=5" target="_blank">Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
What Is the Outlook for Treatment De-Intensification Strategies for Head & Neck Cancer?
Cleveland Clinicgeneral

What Is the Outlook for Treatment De-Intensification Strategies for Head & Neck Cancer?

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcm14dTlCdnpIVGhsVUpGYWhnR1Q1QkNVOEdabHFLc3NTai1YSllsMmNfX2dGZkJMRm9VM2puZ3JsVGR6dmI4cElvUDdreGM1cHNDUjZQNmtDMEJ4Nlg3dDhoOXh4M3duOUYtc041ZzZ3RWZ5VDhwOXlhM3cyOWJmT01CakpJbkowUXdGQXNMVVN2WmJ2QXlXeDVmZm1RdHFwYlk4cDFqQWRXX202V29veFZJV08wa0NuWGFxalV5WmE?oc=5" target="_blank">What Is the Outlook for Treatment De-Intensification Strategies for Head & Neck Cancer?</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
Can ctDNA Guide Immunotherapy in Limited-Stage SCLC?
Medscapeworld

Can ctDNA Guide Immunotherapy in Limited-Stage SCLC?

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPRnFZMXByOHYwUVBvMjhDQ1FwYnNhVUlWbGl6UlFlN0JBYi1nd0lGYzZUSjNiXzNReHViVEhrbVI1UUcwTUs1aXV3ZWxwVG9XcnZvLXNUQ1pZeGVkbFdKSkd2MnpsXzk1bVgyYzZyTWtscmhocGlBOWF5OEpPa2ZoRzJzQzdKOUNQS01JNlhBOS1PdzVJb1V4VmNiNEJVVVU?oc=5" target="_blank">Can ctDNA Guide Immunotherapy in Limited-Stage SCLC?</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Clinical Trial Hopes to Boost Survival Rates with Personalized Treatment for Extensive-Stage Small Cell Lung Cancer
Roswell Park Comprehensive Cancer Centerworld

Clinical Trial Hopes to Boost Survival Rates with Personalized Treatment for Extensive-Stage Small Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxOZk5uT2xUb1FxNEtMTzhlRjhTckVyTVNYWDAwd2Npdld2QVhWWXd2Y3pYQUNOeHVicnhQcDBCZV9GcXRLX3NncGtfdnBkc3JrMTVZUUdaaFdaaHQxNVZlNW10ejBSRVpRMUcyeUEtR292QmJMejJwQmJacklEcF8zUnFNR19tcEVuMFFMOEx3dWtNNkZGWDZtRjdxMWJ3RUFBRk13VURoNnQyaXllRnBRei1iNHJPVlZXNWF6cTZrUEVwVEI3YXNDRE8tdHpRVXZkcy1qazM5VHhLZnRRc2VlUUhqZnRoanFfUDRoSjRTa1gtMWVlRkE?oc=5" target="_blank">Clinical Trial Hopes to Boost Survival Rates with Personalized Treatment for Extensive-Stage Small Cell Lung Cancer</a>  <font color="#6f6f6f">Roswell Park Comprehensive Cancer Center</font>

Read Full StoryMore like this
Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report
Frontiersgeneral

Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxObGEyQ2ZMQW8zdlpLQVNUWENmTGVNS3Myc0NrMXlPeVBUTTJWSzVOaEhndGVmeTBOOGV0YmplY3hlc2prdU5jUm93NW9MUlFGbTVxckVqd2dhalk5NW1Dd2F1RG1aMnhhakNqMFFtQ3ZnaVlMTUJvekdVMVZVVFV3M3hSVmNUN1Bhb2sxSWg2QVZhUQ?oc=5" target="_blank">Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Atezolizumab Induction Chemoimmunotherapy Showed “Encouraging Survival” in Stage III NSCLC
Oncology News Centralworld

Atezolizumab Induction Chemoimmunotherapy Showed “Encouraging Survival” in Stage III NSCLC

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNRGY3YmhQRTAxVjVJLW5tNGZNUF8yVVpXU1FfWWFUMkdqb0x1M2JIMVdCQmhVQkE4ajQ4NndmSzBMejZ0OTdQMEdpQURxZk5aMWxjVjExaHBxa05fYUFIZjBicm1Ma1FJdUhrRzhlUGpPamt0VU9PY0RDc1RQSHBCODRBOHBudWpoV2ZBTnNuZWxoR1ZFMWNoQmFsWHhwTmt1cHdSaVV3ZVJnSHN5azZ5LTlVV2pXazdVYmhoY2loNVdiVTZfWFZ4U3hn?oc=5" target="_blank">Atezolizumab Induction Chemoimmunotherapy Showed “Encouraging Survival” in Stage III NSCLC</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Factors affecting prognosis in patients with locally advanced and advanced esophageal cancer receiving definitive radiotherapy in plateau regions
Naturegeneral

Factors affecting prognosis in patients with locally advanced and advanced esophageal cancer receiving definitive radiotherapy in plateau regions

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5SYjU1Q3l2UTByRXNaSzZGWjEta09wT2hsTm1JNk1FU0VBWnZ0enR4ZHZEYnBKUTBzc29vSXJaVVFseTh0WmNtMXB2MWhNVm5EdzB1blNUTnNmRklYeDZ3?oc=5" target="_blank">Factors affecting prognosis in patients with locally advanced and advanced esophageal cancer receiving definitive radiotherapy in plateau regions</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
INCREASE Trial Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC
The ASCO Postworld

INCREASE Trial Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNLVZMa2pHS2pLaEZOb2hhcmVZZ2lGV2JRVGZhUDhrRGRGaEs0NTBCTkQ5UmNzdEpBVzVHWjFLOVNBcE05UU42ek4wZ3Vic2xjdmxYVjdReHk2dVpFcmg1YXZuTjQwbVpOc1NZa3ZhRGdaeHRkN3BsZDFWWnZHREFaaWJXVG5xU2pUc3VaeGdBdjliRlJ4SF9wMGZZZWFnZGJUV2RtRWNESnFTbjFWd3lNLXY4eFlHNy05RGtON3BnVy1VQUQ5MmtBa0g5a2pFUGlwTWl6bHFfRXZ1Wll0RHdRMU13?oc=5" target="_blank">INCREASE Trial Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
Frontiersworld

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPWm1qV0QzYWlIdkR0dmJTajdTNlFiZ0FVQlVwVnNxVF9iMHlXdjBLd2ptTmt4ei1oNnh1eVlxZHJQeW9QTWl0dkxtVkUtTVZJRlRnOE9BZHBnOHVfaXFTYUF1R045dG9aWEd2ZVBHZDI1bTA4S0dXY0M4ZWpFdVZwRnZBcEJNc3lJWW1Ybw?oc=5" target="_blank">Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report
Frontiersscience

Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPT3lNSndpRVladzlZT1dfZTh4RW5JRGZrV2hGQmwxMFlJNEQ4UGh5bnE2ZHRhemt5U1h4YmRTcDBXVlhCVFFNV1hGRk1IdTJmLTlRNDRkdUwxR1ctSU5zRWFQQk5CYkdoNVlOVFRHT0xRWTRSLXBjRnFWVGtiVGZNaXNvSmZuRXd4ck1sNFFR?oc=5" target="_blank">Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Natureworld

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE01bjNpbVlJVjZrOXpDbVpWSm5yQXpoRjVrWDlSSXFIRTd5ZEZETURXcGtsdjViLW5KYWoyQlVhMS1sTGhlMEJxUTFDdHhEbDdtWEFvQnNxS1Y2S0dPQTZJ?oc=5" target="_blank">Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Induction chemo-immunothe" — Live Google News Trends & Headlines